PIN70 Epidemiological And Economic Burden Of Surgical Site Infections (SSIS) Associated With Hip Arthroplasty  by Patel, H. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A277
plasty—compared to non-infected patients— ranged from 5.4 to 54 days. Differences 
in populations and outcome measures in studies evaluating mortality, readmissions 
and costs due to SSIs associated with hip arthroplasty precluded group analysis. 
A representative example of results from one US study reported the average total 
charges (in 2006 US$) of treating SSIs in patients who underwent primary total hip 
arthroplasty to be $73,452 compared to $38,588 to treat non-infected patients. In 
addition, a UK study showed that treating MRSA infections further exacerbated out-
comes, with excess mean LOS of 14 days and increased costs of £4,465 compared to 
non-MRSA infections in 2004. ConClusions: SSI infections after hip arthroplasty 
impose additional cost; an important portion of SSIs are associated with S. aureus. 
An unmet need for targeted preventive strategies to reduce the consequences of 
SSIs is highlighted.
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objeCtives: In a real-world setting, adherence to antiviral therapies is often sub-
par and treatment outcomes are consequently compromised. This study evaluated 
the adherence rate to HCV therapy in a Medicaid population. Methods: Patients 
eligible for this study were Texas Medicaid patients ≥ 18 years who had evidence of 
chronic HCV during the identification period (1/1/07 – 9/30/11) and were continu-
ously enrolled throughout the assessment period. Primary outcome was adher-
ence to pegylated interferon (Peg-IFN) and telaprevir (TLV) or boceprevir (BOC) as 
measured by proportion of days covered (PDC) using refill history. Univariate and 
multivariate logistic regression analysis evaluated predictors for adherence, such 
as age (< 55, ≥ 55), gender, Charlson comorbidity index (CCI), race (Whites vs. Non-
Whites), presence of medical/psychosocial comorbidities, number of prescription 
drugs and office visits (intervals of 10), and evidence of adherence to other chronic 
medications (coronary artery disease and diabetes). Results: A total of 24,032 
patients were identified as having chronic HCV; 9.4% with evidence of receiving 
HCV treatment. Of those treated, 11.2% were initiated on therapy with either TLV 
or BOC in 2011. The average HCV medication PDC was 70% with a significant dif-
ference between the first 12 weeks and the following 12 weeks of therapy (79% vs. 
60%, p< 0.001). Significant positive independent predictors of HCV medication PDC 
greater than 70% included male gender (OR: 1.42, 95% CI: 1.08-1.86), higher number 
of non-HCV prescription drugs (OR: 1.11, 95% CI: 1.02-1.21) and higher number of 
outpatient visits (OR: 1.19, 95% CI: 1.08-1.31). Age, CCI, race and adherence levels 
to other chronic medications were not significant independent predictors for HCV 
medication PDC. ConClusions: Overall adherence for HCV therapy was poor 
(70%), especially after the initial 12 weeks of therapy (60%). Closer follow-up and 
management of other comorbidities may improve readiness to HCV therapy and 
improve treatment adherence.
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objeCtives: Adults with immunocompromising conditions have higher chances 
of developing pneumococcal disease and should receive pneumococcal vaccination 
based on the recommendations by U.S. Centers for Disease Control and Prevention. 
This study examined pneumococcal vaccination in immunocompromised adults, 
including patients with chronic renal disease (CRD), cancer, HIV infection, and 
patients who underwent transplant. Methods: A large administrative claims 
database was used to assess the pneumococcal vaccination among adults aged 
19-64 years who were newly diagnosed with CRD, cancer, HIV, or patients underwent 
organ transplant procedure during 2007-2010. These patients were followed until 
2011 or the end of enrollment to identify whether they received pneumococcal vac-
cination after the diagnosis or procedure. Multivariate logistic regression was used 
to examine patients characteristics associated with pneumococcal vaccination cov-
erage. Results: We identified 22,862 patients with CRD, 216,658 with cancer, 2,576 
with HIV infection, and 41,889 patients underwent transplant procedure during the 
study period. The pneumococcal vaccination coverage were 7.3% among patients 
with newly diagnosed with CRD, 4.8% among cancer patients, 31.0% among HIV 
patients, and 5.2% among patients underwent transplant. Immunocompromised 
patients with more hospitalizations during the follow-up period had higher cover-
age, except for HIV patients. Coverage was consistently higher with more visits 
to doctor office and pharmacy across all immunocompromising conditions. The 
majority of immunocompromised patients received their vaccines at the primary 
care physician’s (PCP) office (68.4% among patients with CRD, 70.0% among can-
cer, and 75.0% among transplant) except for HIV patients (45.2% at PCP office vs. 
45.7% at specialist office). Vaccination out-of-pocket costs ranged from $3.41 (HIV) 
to $11.06(CRD) for immunocompromised patients. ConClusions: Pneumococcal 
vaccination coverage was highest in HIV patients and lowest in cancer patients 
among all immunocompromising conditions. However, even HIV population did not 
meet Healthy people 2020 target for immunocompromised patients (60%). A more 
efficient immunization strategy should be developed to improve pneumococcal 
vaccination coverage for the immunocompromised adults.
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relative to IIV3, IIV4 is expected to avert an additional 2,516 influenza cases, 1,683 
influenza-associated medical visits, 27 influenza-associated hospitalizations and 
5 influenza-associated deaths. From a societal perspective IIV4 would generate 76 
more QALYs and a net societal budget impact of $2,265,769. The incremental cost 
effectiveness ratio (ICER) for this comparison was $29,738/QALY. 74% of simulations 
in a probabilistic sensitivity analysis were below $100,000/QALY and 29% were domi-
nant. In a scenario analysis, the ICER was $94,248 per QALY from a third party payer 
perspective. ConClusions: IIV4 is expected to achieve reductions in influenza 
related morbidity and mortality compared to IIV3. Further, despite not accounting 
for herd protection IIV4 is still expected to be a cost effective alternative to IIV3. Our 
conclusions were robust in the face of sensitivity analyses.
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objeCtives: The aim of this study is to assess the economic impact of new strate-
gies involving the administration of triple therapy (PEG IFN , ribavirin and telaprevir 
or boceprevir) to naive patients with chronic hepatitis C (CHC). Methods: eco-
nomic results were evaluated along a 30 – years time horizon. Seven health states 
were considered in our model: CHC genotype 1, sustained virologic response (SVR), 
compensated cirrhosis, decompensated cirrhosis, HCC, liver transplantation and 
death. The effectiveness of telaprevir in naïve patients was inferred from ADVANCE 
trial, whilst the effectiveness of boceprevir was inferred from the SPRINT 2 trial. 
Quality of life (QoL) scores were used to adjust the years gained by patients enrolled 
in the model. Resource consumption was estimated from the Italian SSN perspec-
tive. Costs and benefits were discounted at a rate of 3.5%. To map the uncertainty of 
the model resulting from the Bayesian analysis, a probabilistic sensitivity analysis 
was carried out. Results: In both cases the ICER is likely to be under an hypotheti-
cal threshold of € 20.000 – 30.000. However, strategy which includes treatment with 
teelaprevir is proven to have a more favorable cost effectiveness ratio.(€ 12.000 vs € 
14.000). In the case of telaprevir probability of being under the threshold of € 30.000/
QALY is 100/, whist for Boceprevir probability is 70%. ConClusions: In general, the 
provision of either telaprevir and boceprevir was proved to be affordable compared 
to the standard of care.
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objeCtives: An elevated number of absence days and disability affect both employ-
ers and employees as a result of pneumococcal diseases. This study aims to estimate 
the impact of a 13-Valent Pneumococcal vaccination program from employer´s per-
spective in a medium size Mexican-Corporate setting. Methods: A decision tree 
was built in order to estimate yearly productivity losses and absence days avoided, 
as well as pneumococcal disease treatment costs. Local incidence of pneumococ-
cal diseases as well as mortality rates were extracted from published and Mexican 
Government databases. Treatment costs were retrieved from the most representa-
tive Mexican public health care provider. The cost of the vaccine was provided by the 
manufacturer. A base scenario of a 1,000 employee company with a homogeneous 
distribution of ages (18< x< 65) was assumed to show the potential benefits of the 
program in patients between 50 and 65 years old (average monthly wage: US$779). 
Productivity losses are expressed in 2013 US$ (5% discount rate/year). A bivari-
ate sensitivity analysis of both, vaccine cost (+10%) and effectiveness (-10%) was 
performed. Results: Assuming 50% employee enrollment into the program, and 
vaccination cost split 50/50 between employer and employee, a single employer 
investment of US$50 per program participant could potentially generate savings 
of US$33 for each over a ten year horizon. We estimate 395 absence days can be 
avoided, representing avoided productivity losses as high as US$8,315 across all 
participants in ten years. The program becomes cost-saving at year 7, however 
absences are avoided from the first year. The total treatment plus productivity 
losses of an invasive infection, in- and outpatient pneumonia are respectively 54, 
34 and 47 times higher than the vaccination outlay. Outcomes were robust to a 10% 
variation in both vaccination cost and effectiveness. ConClusions: A 13-Valent 
Pneumococcal vaccination program could bring potential savings for employers 
from the seventh year of implementation.
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objeCtives: SSIs are post-surgical complications that are associated with substan-
tial economic burden. Patients who undergo hip arthroplasty may develop SSIs, 
with seriously affected individuals typically requiring costly interventions including 
revision surgery or possibly removal of prostheses. The objective is to review the 
global epidemiology and burden of SSIs following hip arthroplasty, with a focus on 
Staphylococcus aureus (S. aureus). Methods: A comprehensive search was conducted 
in PubMed and relevant conference abstracts; 240 publications were reviewed to 
identify the epidemiology and burden of SSIs associated with hip arthroplasty pub-
lished between 2003 and 2013. Results: The median SSI infection rate as a percent 
of all hip arthroplasties was 1.8% (range: 0.05%-28%). Median 44% (18%-60%) of 
SSIs after hip arthroplasty were attributed to S.aureus. Methicillin-resistant S.aureus 
(MRSA) infection rates (% all S.aureus infections) from three studies were calculated 
as 16%, 31% and 56%, with variations in the range likely due to small sample size. 
Length of stay (LOS) prolongation for patients who developed SSIs after hip arthro-
